Alice L Yu Selected Research

dinutuximab

12/2022	Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group.
1/2021	Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.
11/2020	Targeting glycosphingolipids for cancer immunotherapy.
1/2020	Anti-GD2 induced allodynia in rats can be reduced by pretreatment with DFMO.
1/2020	Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.
1/2018	A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.
1/2018	Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.
1/2017	Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
1/2017	HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.
1/2014	Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alice L Yu Research Topics

Disease

52	Neoplasms (Cancer) 01/2022 - 11/2002
31	Neuroblastoma 12/2022 - 05/2002
23	Breast Neoplasms (Breast Cancer) 01/2022 - 08/2008
6	Pain (Aches) 01/2020 - 01/2009
6	Macular Degeneration (Age-Related Maculopathy) 12/2014 - 04/2008
6	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 11/2010 - 03/2002
5	Infections 01/2017 - 06/2006
5	Glaucoma 01/2015 - 11/2008
4	Fever (Fevers) 12/2022 - 01/2009
4	Neoplasm Metastasis (Metastasis) 01/2021 - 10/2011
4	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 02/2006 - 03/2002
3	Hypersensitivity (Allergy) 12/2022 - 09/2010
3	Hypotension (Low Blood Pressure) 12/2022 - 01/2009
3	Hyperalgesia 01/2020 - 04/2010
3	Capillary Leak Syndrome 01/2018 - 01/2009
3	Hypoxia (Hypoxemia) 01/2017 - 04/2007
3	Kidney Neoplasms (Kidney Cancer) 01/2017 - 08/2013
3	Leukemia 10/2012 - 11/2002
2	Disease Progression 01/2022 - 05/2013
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2017 - 08/2013
2	Residual Neoplasm 12/2014 - 09/2013
2	Optic Nerve Diseases (Optic Neuropathy) 03/2013 - 01/2012
2	Lung Neoplasms (Lung Cancer) 01/2013 - 06/2007
1	Mouth Neoplasms (Oral Cancer) 01/2022
1	Cholangiocarcinoma 01/2022
1	Ankylosing Spondylitis 06/2021
1	Edema (Dropsy) 01/2021

Drug/Important Bio-Agent (IBA)

14	dinutuximabIBA 12/2022 - 01/2009
14	Proteins (Proteins, Gene)FDA Link 01/2021 - 10/2004
12	Globo-HIBA 01/2022 - 08/2008
9	Monoclonal AntibodiesIBA 01/2017 - 04/2010
8	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 12/2022 - 01/2009
8	Messenger RNA (mRNA)IBA 01/2022 - 04/2007
8	Polysaccharides (Glycans)IBA 01/2021 - 08/2008
8	GlycolipidsIBA 11/2020 - 06/2007
7	Interleukin-2 (IL2)IBA 12/2022 - 01/2009
7	Pharmaceutical PreparationsIBA 01/2022 - 11/2002
7	Isotretinoin (Accutane)FDA LinkGeneric 01/2018 - 09/2010
6	AntioxidantsIBA 12/2014 - 04/2008
5	Aldehyde DehydrogenaseIBA 01/2021 - 10/2011
4	VaccinesIBA 01/2022 - 08/2008
4	Biomarkers (Surrogate Marker)IBA 12/2021 - 10/2010
4	CytokinesIBA 01/2021 - 06/2007
4	Galactosylceramides (Galactocerebrosides)IBA 02/2014 - 04/2011
4	AntibodiesIBA 01/2014 - 08/2008
3	AntigensIBA 01/2022 - 06/2006
3	RNA (Ribonucleic Acid)IBA 01/2022 - 10/2004
3	CarbohydratesIBA 01/2022 - 08/2008
3	CeramidesIBA 01/2022 - 12/2014
3	LigandsIBA 12/2021 - 01/2017
3	LipidsIBA 01/2021 - 01/2017
3	GlycosphingolipidsIBA 11/2020 - 10/2016
3	EpitopesIBA 01/2020 - 08/2008
3	englerin AIBA 01/2017 - 08/2013
3	VimentinIBA 08/2014 - 10/2011
2	globo H-KLH vaccineIBA 01/2022 - 01/2020
2	Immunoglobulin G (IgG)IBA 01/2022 - 02/2013
2	Glycoproteins (Glycoprotein)IBA 01/2021 - 12/2012
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 11/2002
2	Complement System Proteins (Complement)IBA 01/2021 - 04/2010
2	Small Interfering RNA (siRNA)IBA 01/2021 - 05/2009
2	Hormones (Hormone)IBA 07/2020 - 01/2020
2	Temozolomide (Temodar)FDA LinkGeneric 01/2020 - 01/2017
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2020 - 01/2017
2	Cell-Free Nucleic AcidsIBA 01/2019 - 01/2018
2	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 10/2004
2	Plant ExtractsIBA 01/2017 - 08/2013
2	Protein Isoforms (Isoforms)IBA 01/2017 - 04/2007
2	Peptides (Polypeptides)IBA 01/2016 - 04/2012
2	Biological ProductsIBA 07/2014 - 08/2013
2	3-Iodobenzylguanidine (Iobenguane)IBA 09/2013 - 05/2012
2	Phosphotransferases (Kinase)IBA 08/2013 - 10/2004
2	Stage-Specific Embryonic AntigensIBA 02/2013 - 08/2008
2	MicroRNAs (MicroRNA)IBA 01/2013 - 10/2010
2	GangliosidesIBA 12/2012 - 04/2010
2	cluvenoneIBA 10/2012 - 11/2010
2	Transforming Growth Factor beta (TGF-beta)IBA 02/2009 - 04/2007
2	alpha-galactosylceramideIBA 08/2008 - 06/2007
1	Matrix Metalloproteinase 1 (Interstitial Collagenase)IBA 01/2022
1	NucleophosminIBA 01/2022
1	Immunoglobulin M (IgM)IBA 01/2022
1	Thioacetamide (Thioacetamid)IBA 01/2022
1	Staphylococcal Protein A (Protein A)IBA 12/2021
1	micaIBA 06/2021
1	Polycyclic Aromatic Hydrocarbons (Polynuclear Aromatic Hydrocarbons)IBA 03/2021
1	Environmental Pollutants (Pollutants, Environmental)IBA 03/2021
1	ibrutinibIBA 02/2021
1	atezolizumabIBA 02/2021
1	Interleukin-15 (Interleukin 15)IBA 02/2021
1	MorpholinosIBA 01/2021
1	GlycosyltransferasesIBA 01/2021
1	OligosaccharidesIBA 01/2021

Therapy/Procedure

34	Therapeutics 12/2022 - 05/2002
19	Immunotherapy 12/2022 - 08/2008
4	Drug Therapy (Chemotherapy) 07/2019 - 03/2002
3	Precision Medicine 01/2022 - 01/2022
3	Stem Cell Transplantation 09/2013 - 09/2010
2	Induction Chemotherapy 11/2019 - 09/2013
2	Radiotherapy 07/2019 - 09/2013
2	Bone Marrow Transplantation (Transplantation, Bone Marrow) 09/2013 - 01/2009